# Multicenter Clinical Study on the Efficacy and Safety of Xiyanping Injection in the Treatment of New Coronavirus Infection Pneumonia (General and Severe)

> **NCT04295551** · NA · UNKNOWN · sponsor: **Jiangxi Qingfeng Pharmaceutical Co. Ltd.** · enrollment: 80 (estimated)

## Conditions studied

- COVID-19

## Interventions

- **DRUG:** Lopinavir / ritonavir tablets combined with Xiyanping injection
- **DRUG:** Lopinavir/ritonavir treatment

## Key facts

- **NCT ID:** NCT04295551
- **Lead sponsor:** Jiangxi Qingfeng Pharmaceutical Co. Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-03-14
- **Primary completion:** 2020-07-14
- **Final completion:** 2021-04-14
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2020-03-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04295551

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04295551, "Multicenter Clinical Study on the Efficacy and Safety of Xiyanping Injection in the Treatment of New Coronavirus Infection Pneumonia (General and Severe)". Retrieved via AI Analytics 2026-07-02 from https://api.ai-analytics.org/clinical/NCT04295551. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*